DexCom Cash & Equivalents increased by 21.7% to $1.12B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.4%, from $906.10M to $1.12B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 2.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
A universal metric for assessing a company's immediate financial health.
cash_and_equivalents| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.16B | $1.45B | $1.05B | $716.00M | $736.40M | $699.10M | $643.30M | $624.30M | $1.20B | $644.80M | $567.50M | $852.40M | $940.50M | $622.40M | $607.30M | $906.10M | $1.16B | $1.84B | $919.10M | $1.12B |
| QoQ Change | — | +24.7% | -27.1% | -32.0% | +2.8% | -5.1% | -8.0% | -3.0% | +91.6% | -46.1% | -12.0% | +50.2% | +10.3% | -33.8% | -2.4% | +49.2% | +28.1% | +58.3% | -50.0% | +21.7% |
| YoY Change | — | — | — | — | -36.5% | -51.6% | -38.9% | -12.8% | +62.4% | -7.8% | -11.8% | +36.5% | -21.4% | -3.5% | +7.0% | +6.3% | +23.4% | +195.1% | +51.3% | +23.4% |